Patent search ap:("Merck Sharp & Dohme Corp.") AND inv:"Kun Liu" Page 2

11.

发明申请
9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE 有权

公开(公告)号：US20220220117A1

公开(公告)日：2022-07-14

申请号：US17657515

申请日：2022-03-31

Applicant: Merck Sharp & Dohme Corp.

Inventor： Matthew A. Larsen , Amjad Ali , Jared Cumming , Duane DeMong , Qiaolin Deng , Thomas H. Graham , Elisabeth Hennessy , Andrew J. Hoover , Ping Liu , Kun Liu , Umar Faruk Mansoor , Jianping Pan , Christopher W. Plummer , Aaron Sather , Uma Swaminathan , Huijun Wang , Yonglian Zhang

IPC: C07D487/04

Abstract: In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

12.

发明授权
Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors 有权

公开(公告)号：US11111232B2

公开(公告)日：2021-09-07

申请号：US16753050

申请日：2018-10-04

Applicant: MERCK SHARP & DOHME CORP.

Inventor： Catherine M. White , Abdelghani Achab , Indu T. Bharathan , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Meredeth Ann McGowan , Nunzio Sciammetta , Wensheng Yu , Hongjun Zhang , Hua Zhou

IPC: A61K31/4418 , C07D401/14 , C07D213/74 , C07D401/12 , C07D405/12 , C07D413/14 , C07D417/14

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

13.

发明申请
NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS 有权

公开(公告)号：US20210179607A1

公开(公告)日：2021-06-17

申请号：US16758717

申请日：2018-10-29

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yongqi Deng , Abdelghani Achab , Bridget A. Becker , David Jonathan Bennett , Indu Bharathan , Xavier Fradera , Craig Gibeau , Yongxin Han , Derun Li , Kun Liu , Qinglin Pu , Sulagna Sanyal , David Sloman , Wensheng Yu , Hongjun Zhang

IPC: C07D471/04 , C07D215/14 , A61K45/06

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

14.

发明申请
9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE 有权

公开(公告)号：US20210107904A1

公开(公告)日：2021-04-15

申请号：US16695367

申请日：2019-11-26

Applicant: Merck Sharp & Dohme Corp.

Inventor： Matthew A. Larsen , Amjad Ali , Jared Cumming , Duane DeMong , Qiaolin Deng , Thomas H. Graham , Elisabeth Hennessy , Andrew J. Hoover , Ping Liu , Kun Liu , Umar Faruk Mansoor , Jianping Pan , Christopher W. Plummer , Aaron Sather , Uma Swaminathan , Huijun Wang , Yonglian Zhang

IPC: C07D487/04

Abstract: In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

15.

发明授权
Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors 有权

公开(公告)号：US10927086B2

公开(公告)日：2021-02-23

申请号：US16483957

申请日：2018-02-19

Applicant: Merck Sharp & Dohme Corp. , Kun Liu , Dane Clausen , Liangqin Guo , Yongxin Han , Shuwen He , Joseph Kozlowski , Derun Li , Qinglin Pu , Wensheng Yu , Hongjun Zhang

Inventor： Kun Liu , Dane Clausen , Liangqin Guo , Yongxin Han , Shuwen He , Joseph Kozlowski , Derun Li , Qinglin Pu , Wensheng Yu , Hongjun Zhang

IPC: C07D271/08 , C07D413/12

Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

16.

发明申请
TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE 审中-公开

公开(公告)号：US20190292159A1

公开(公告)日：2019-09-26

申请号：US16270882

申请日：2019-02-08

Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation

Inventor： Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov

IPC: C07D265/36 , C07D413/12 , A61K31/4709 , C07D413/06 , C07D487/04 , C07D417/06 , C07D471/04 , C07D413/04 , C07D401/12 , C07D401/06 , C07D215/58 , C07D413/14 , A61K45/06 , A61K31/538 , A61K31/4375 , A61K31/47

Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.

17.

发明授权
Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof 有权

公开(公告)号：US10344000B2

公开(公告)日：2019-07-09

申请号：US15770255

申请日：2016-10-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Blair T. Lapointe , Peter H. Fuller , Hakan Gunaydin , Kun Liu , Danielle F. Molinari , Qinglin Pu , Mark E. Scott , B. Wesley Trotter , Hongjun Zhang

IPC: C07D231/56 , C07D401/04 , C07D491/052 , C07D491/107 , A61P19/02 , A61P17/06 , A61P29/00 , A61P37/02 , A61P11/06 , C07D471/04

Abstract: The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

18.

发明申请
HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORgammaT INHIBITORS AND USES THEREOF 审中-公开

公开(公告)号：US20190194186A1

公开(公告)日：2019-06-27

申请号：US15770257

申请日：2016-10-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Hongjun Zhang , Kenneth Jay Barr , Blair T. Lapointe , Hakan Gunaydin , Kun Liu , B. Wesley Trotter

IPC: C07D471/04 , A61P37/00 , A61P29/00 , A61P19/02 , A61P11/06

CPC classification number: C07D471/04 , A61P11/06 , A61P19/02 , A61P29/00 , A61P37/00

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.